Markus Borner

Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

Stephen Chan, M. E. Scheulen, S. Johnston et al. · Journal of Clinical Oncology · 2005 · 468 citations · Full text

Medicine, Oncology, Pharmacology +16

The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression

Silvia Vonlanthen, Jim Heighway, H. J. Altermatt et al. · British Journal of Cancer · 2001 · 298 citations · Full text

Life Sciences, Genetics, Oncology +17

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

Werner Scheithauer, J McKendrick, S. Begbie et al. · Annals of Oncology · 2003 · 275 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Comparative Study of Tegafur/Uracil and Oral Leucovorin Versus Parenteral Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer

James Carmichael, Tadeusz Popiela, David Radstone et al. · Journal of Clinical Oncology · 2002 · 267 citations

Medicine, Oncology, Pharmacology +15

Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research

Arnaud Roth, Nicola Fazio, Roger Stupp et al. · Journal of Clinical Oncology · 2007 · 244 citations · Full text

Medicine, Oncology, Pharmacology +14